Unbound MEDLINE

Angiotensin-converting enzyme inhibitors and obstructive sleep apnea. Mayo Clinic proceedings. Mayo Clinic. [Mayo Clin Proc] Journal article

 
TitleAngiotensin-converting enzyme inhibitors and obstructive sleep apnea.
Author(s)Cicolin A, Mangiardi L, Mutani R, Bucca C 
InstitutionDepartment of Neurosciences, Sleep Medicine Center, University of Turin, Turin, Italy.
SourceMayo Clin Proc 2006 Jan; 81(1):53-5.
MeSHAged
Angiotensin-Converting Enzyme Inhibitors
Breath Tests
Enalapril
Female
Follow-Up Studies
Humans
Hypertension
Male
Middle Aged
Polysomnography
Research Support, Non-U.S. Gov't
Risk Factors
Sleep
Sleep Apnea, Obstructive
AbstractAngiotensin-converting enzyme (ACE) inhibitors may induce cough and rhinopharyngeal inflammation. Obstructive sleep apnea (OSA) is characterized by upper airway inflammation. We describe a patient who, during enalapril treatment, developed cough, upper airway symptoms, and diurnal sleepiness, with an increased number of obstructive apnea-hypopnea episodes (apnea-hypopnea index [AHI], 25) during sleep. Her symptoms and AHI improved 1 month after enalapril was discontinued and diuretic therapy (hydrochlorothiazide-spironolactone) was initiated. Similar findings were observed in 4 other patients with OSA who had ACE inhibitor-induced cough. The mean +/- SD AHI was 33.8+/-21.0 during enalapril treatment and 20.0+/-17.0 after withdrawal of this drug (P = .04). Exhaled nitric oxide, a marker of airway inflammation, was increased during enalapril treatment (15.0 +/- 4.3 parts per billion) and decreased after discontinuation of this drug (9.0 +/- 2.6; P = .03). No significant difference in the AHI and exhaled nitric oxide was observed in 4 patients with OSA who did not experience cough, before or after withdrawal of ACE inhibitor treatment. These findings suggest that ACE inhibitor treatment may contribute to OSA by inducing upper airway inflammation.
Languageeng
Pub Type(s)Case Reports
Journal Article
PubMed ID16438479
  
Advertise on this site.